Tafalgie Therapeutics is going to participate in the ‘IPOready’ 2024 program, a pre-IPO program organized by Euronext for the 9th consecutive year

Tafalgie Therapeutics, a biopharmaceutical research company specialised in the research and innovation of treatments capable of alleviating and preventing the onset of acute and chronic pain (inflammatory, post-operative, neuropathic) without side effects, is proud to announce that it has been selected to take part in the ‘IPOready’ 2024 program aimed at supporting fast-growing European companies which may become listed on Euronext.

In order to accelerate its development, Tafalgie Therapeutics and its management team will thus have all the tools and information they need to consider setting up a potential IPO process in the coming years.

Tafalgie Therapeutics will take part in this program alongside more than 160 companies from 15 European countries this year. This figure testifies to the dynamism of a pool of ambitious, fast-growing companies considering an European listing, and the relevance of Euronext as Europe’s leading listing platform.

Visit our contact page